Medtronic (NYSE:MDT) on Thursday announced 510((k)) regulatory submissions in the U.S. to seek FDA clearance for an insulin pump developed with Abbott Laboratories (NYSE:ABT) as part of a 2024 collaboration.
The 510((k)) applications focus on an interoperable pump designed to integrate
